Madrigal Pharmaceuticals, Inc. (MDGL) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH).
Is Madrigal Pharmaceuticals, Inc. stock overvalued or undervalued in 2026?
As of November 3, 2026, Madrigal Pharmaceuticals, Inc. (MDGL) trades at $396.32 with no positive earnings over the last twelve months, according to Kaplio. No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: Madrigal Pharmaceuticals, Inc.
Market cap $9B · 52 weeks $396 – $603 (28 % below the high) · P/E no earnings · 2027 est. P/E 69.0× · Dividend none · Next earnings February 18, 2027 · expected EPS -$0.11 · Closing price, Nov 3 · accounts published Nov 3.
- Valuation: P/Sales 7.5× (no earnings).
- Balance sheet: Safe zone (solid).
- Earnings: 6 of 8 (no verdict).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 2 of 4 pass
- R&D / Market cap 4.4 %, fails.
- Market cap / Cash 9.0×, fails.
- Cash Runway 62 months, passes.
- Total Debt 0.4×, passes.
- Annual cash burn $8.45, info.
Against its peers (reference peers) — Madrigal Pharmaceuticals, Inc.: P/E —; EV/EBITDA —; ROIC -15.6 %; $9.2B. Protagonist Therapeutics, Inc. (P/E 136×; EV/EBITDA 100×; ROIC 6.7 %; $9.1B), Caris Life Sciences, Inc. (P/E 91.8×; EV/EBITDA 54.8×; ROIC 14.7 %; $9.3B), Krystal Biotech, Inc. (P/E 41.4×; EV/EBITDA 34.4×; ROIC 15.8 %; $9.0B).
Profitability
| Return on Equity | -27.07% |
| Return on Invested Capital | -15.56% |
| Return on Assets | -10.84% |
| Gross Margin | 90.96% |
| Operating Margin | -10.69% |
| Net Margin | -10.89% |
Financial Health
| Debt / Equity | 0.56 |
| Current Ratio | 3.05 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 10.48 |
Price Performance
| 1 month | -12.65% |
| 3 months | -15.52% |
| Year-to-date | -25.96% |
| 1 year | -3.03% |
| 3 years | +193.53% |
| 5 years | +363.41% |
| 10 years | +2683.47% |
Related companies: NAMS · VKTX · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX
Explore sector: Healthcare · Biotechnology
More sections of MDGL: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks